Caribou Biosciences announced October 6, 2026, that it is evaluating strategic alternatives to maximize stockholder value and plans to discontinue further development of its 2 allogeneic chimeric antigen receptor T cell (CAR-T) therapy programs, vispacabtagene regedleucel (vispa-cel; formerly CB-010) for relapsed or refractory (r/r) B cell non-Hodgkin lymphoma and CB-011 for r/r multiple myeloma.¹ The company will implement workforce and cost reductions alongside the decision and reported $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026.¹
Key facts
- Programs discontinued: Vispa-cel (CB-010; anti-CD19, PD-1 knockout) for r/r B-NHL; CB-011 (anti-BCMA, immune-cloaked) for r/r multiple myeloma
- Reason cited: Difficult financing environment for allogeneic CAR-T cell therapies
- Corporate action: Board evaluating strategic alternatives, including merger, acquisition, or sale; Wedbush Securities as financial advisor
- Financial position: $113.8 million in cash, cash equivalents, and marketable securities as of June 30, 2026
- Workforce: Substantial reduction, mostly complete in the 4th quarter of 2026
- Vispa-cel phase 1 data: 82%/86% overall response rate; 64%/63% complete response rate across 2 cohorts
- CB-011 phase 1 data: 92% overall response rate; 91% MRD-negative rate
- Market context: Follows 2026 ex-vivo CAR-T retreats by ArsenalBio, TScan Therapeutics, Cellectis, and Bristol Myers Squibb/Cellares
"This is an extraordinarily difficult decision, particularly because it is in no way a reflection of our belief that vispa-cel and CB-011 have the potential to benefit patients," said Rachel Haurwitz, PhD, president and CEO of Caribou, in a company press release.¹ "Unfortunately, despite the progress we've made, the current financing environment for allogeneic CAR-T cell therapies has made it increasingly challenging to secure the capital necessary to responsibly advance these programs."
What does this strategic evaluation involve?
Caribou's board of directors approved a process that may include a merger, acquisition, business combination, or other strategic transaction involving the company or its assets. Wedbush Securities is serving as exclusive financial advisor to the evaluation. Caribou has not set a timeline for completing the review and does not plan further updates unless the board approves a course of action, the process concludes, or disclosure otherwise becomes appropriate, and the associated workforce reduction is expected to be mostly complete in the 4th quarter of 2026.¹
What had vispa-cel and CB-011 shown before discontinuation?
Vispa-cel, an anti-CD19 CAR-T therapy with a programmed cell death protein 1 knockout designed to limit premature CAR-T cell exhaustion, was pivotal trial-ready, with FDA alignment already reached on its phase 3 design. The candidate held FDA regenerative medicine advanced therapy, fast track, and orphan drug designations for B-cell non-Hodgkin lymphomas.¹ In its phase 1 ANTLER trial, vispa-cel produced overall response rates of 82% and 86% across 2 cohorts, with complete response rates of 64% and 63%, respectively, which Caribou described as on par with approved autologous CAR-T therapies.² CB-011, an anti-B-cell maturation antigen CAR-T therapy engineered with an immune-cloaking strategy, held the same 3 FDA designations for r/r multiple myeloma and produced a 92% overall response rate and 91% minimal-residual-disease-negative rate among evaluable patients in its phase 1 CaMMouflage trial.³
